PMID- 18390969
OWN - NLM
STAT- MEDLINE
DCOM- 20080527
LR  - 20080509
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 26
IP  - 14
DP  - 2008 May 10
TI  - Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study 
      by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
PG  - 2264-71
LID - 10.1200/JCO.2007.14.1366 [doi]
AB  - PURPOSE: Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of 
      non-Hodgkin's lymphomas (NHLs) in adults. ATCLs show a worse prognosis than 
      B-cell lymphomas. PATIENTS AND METHODS: On behalf of the Societe Francaise de 
      Greffe de Moelle et de Therapie Cellulaire, we conducted a retrospective analysis 
      including 77 ATCL patients who underwent allogeneic stem-cell transplantation 
      (alloSCT). RESULTS: The different diagnosis included anaplastic large-cell 
      lymphoma (ALCL; n = 27), peripheral T-cell lymphoma not otherwise specified 
      (PTCL-NOS; n = 27), angioimmunoblastic T-cell lymphoma (AITL; n = 11), 
      hepatosplenic gamma/delta lymphoma (HSL; n = 3), T-cell granular lymphocytic 
      leukemia (T-GLL; n = 1), nasal natural killer (NK)/T-cell lymphoma (nasal-NK/L; n 
      = 3) or non-nasal NK/T-cell lymphoma (non-nasal-NK/L; n = 2), enteropathy-type 
      T-cell (n = 1), and human T-lymphotropic virus (HTLV)-1 lymphoma (n = 2). 
      Fifty-seven patients received a myeloablative conditioning regimen. Donors were 
      human leukocyte antigen (HLA)-matched in 70 cases and related in 60 cases. 
      Thirty-one patients were in complete remission (CR) at the time of alloSCT, 
      whereas 26 were in partial response (PR). Five-year toxicity-related mortality 
      (TRM) incidence was 33% (95% CI, 24% to 46%). The 5-year overall survival (OS) 
      and event-free survival (EFS) rates were 57% (95% CI, 45% to 68%) and 53% (95% 
      CI, 41% to 64%), respectively. In multivariate analysis, chemoresistant disease 
      (stable, refractory, or progressing disease) at the time of alloSCT and the 
      occurrence of severe grade 3 to 4 acute graft-versus-host disease (aGVHD) were 
      the strongest adverse prognostic factors for OS (P = .03 and .03, respectively). 
      Disease status at transplantation significantly influenced the 5-year EFS (P = 
      .003), and an HLA-mismatched donor increased TRM (P = .04). CONCLUSION: We 
      conclude that alloSCT is a potentially efficient therapy for NK/T lymphomas and 
      is worth further investigation through prospective clinical trials.
FAU - Le Gouill, Steven
AU  - Le Gouill S
AD  - Hematology Department, University Hospital, Hotel-Dieu, Nantes, France. 
      steven.legouill@chu-nantes.fr
FAU - Milpied, Noel
AU  - Milpied N
FAU - Buzyn, Agnes
AU  - Buzyn A
FAU - De Latour, Regis Peffault
AU  - De Latour RP
FAU - Vernant, Jean-Paul
AU  - Vernant JP
FAU - Mohty, Mohamad
AU  - Mohty M
FAU - Moles, Marie-Pierre
AU  - Moles MP
FAU - Bouabdallah, Krimo
AU  - Bouabdallah K
FAU - Bulabois, Claude-Eric
AU  - Bulabois CE
FAU - Dupuis, Jehan
AU  - Dupuis J
FAU - Rio, Bernard
AU  - Rio B
FAU - Gratecos, Nicole
AU  - Gratecos N
FAU - Yakoub-Agha, Ibrahim
AU  - Yakoub-Agha I
FAU - Attal, Michel
AU  - Attal M
FAU - Tournilhac, Olivier
AU  - Tournilhac O
FAU - Decaudin, Didier
AU  - Decaudin D
FAU - Bourhis, Jean-Henry
AU  - Bourhis JH
FAU - Blaise, Didier
AU  - Blaise D
FAU - Volteau, Christelle
AU  - Volteau C
FAU - Michallet, Mauricette
AU  - Michallet M
CN  - Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20080407
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Disease/immunology
MH  - Graft vs Tumor Effect/*immunology
MH  - Humans
MH  - Lymphoma, T-Cell/*immunology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Stem Cell Transplantation
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous/immunology
FIR - Harousseau, Jean-Luc
IR  - Harousseau JL
FIR - Contentin, Nathalie
IR  - Contentin N
FIR - Witz, Francis
IR  - Witz F
FIR - Guillerm, Gaelle
IR  - Guillerm G
EDAT- 2008/04/09 09:00
MHDA- 2008/05/28 09:00
CRDT- 2008/04/09 09:00
PHST- 2008/04/09 09:00 [pubmed]
PHST- 2008/05/28 09:00 [medline]
PHST- 2008/04/09 09:00 [entrez]
AID - JCO.2007.14.1366 [pii]
AID - 10.1200/JCO.2007.14.1366 [doi]
PST - ppublish
SO  - J Clin Oncol. 2008 May 10;26(14):2264-71. doi: 10.1200/JCO.2007.14.1366. Epub 
      2008 Apr 7.